FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
vvasiliigtori,	D.C.	20343

OMB APPROVAL								
OMB Number	3235-02							

287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* HOLLER FRANK A				2. Issuer Name and Ticker or Trading Symbol Xenon Pharmaceuticals Inc. [XENE]										all applic	cable) or	g Per	son(s) to Iss	ner		
(Last) (First) (Middle) C/O XENON PHARMACEUTICALS INC						3. Date of Earliest Transaction (Month/Day/Year) 06/01/2017									Officer below)	(give title		Other (s below)	pecify	
200 - 3650 GILMORE WAY					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable						
(Street)	BY A	1	V5G 4W8										X Form filed by One Reporting Person Form filed by More than One Reporting Person							
(City)	(S	tate)	(Zip)																	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da				Execution Date,			Date.	Code (In					4 and Sec Ber Ow		Amount of curities neficially vned Following		n: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
							Code	v	Amount	(A) o	A) or Price		Reported Transact (Instr. 3	ction(s)			(Instr. 4)			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate, Tr	4. Transactio Code (Insti		on of		6. Date Exer Expiration E (Month/Day/	ate		e and 7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		De Se (Ir	3. Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				c	Code		(A)	(D)	Date Exercisable		piration te	Title	Amour or Number of Shares	r						
Stock Option (Right to Buy)	\$3.85	06/01/2017			A		3,500		(1)	05	/31/2027	Common Shares	3,500)	\$0.00	3,500		D		

Explanation of Responses:

1. One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, and the balance of the total shares subject to the Option shall vest on the three year anniversary of the grant date.

/s/ Joanne Smartt, Attorney-in-

06/02/2017

fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.